Clinical Report: EBV-Related Immune Dysregulation in HLH and Lymphoma

Overview

This case study details a 70-year-old female with hemophagocytic lymphohistiocytosis (HLH) as the initial manifestation of multiple myeloma (MM). Despite achieving remission of both conditions, HLH relapsed with persistent Epstein–Barr virus (EBV) viremia, leading to the development of aggressive B-cell lymphoma.

Background

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyper-inflammatory syndrome often triggered by infections, autoimmune diseases, or malignancies. The association between multiple myeloma and HLH is rare, and the emergence of distinct lymphoid neoplasms under EBV-related immune dysregulation is not well characterized. Understanding these relationships is crucial for improving diagnosis and treatment strategies.

Data Highlights

Key Findings

• HLH was diagnosed based on the fulfillment of 5 out of 8 HLH-2004 criteria.
• Multiple myeloma was established through bone marrow examination revealing increased plasma cells and cytogenetic abnormalities.
• EBV viremia persisted despite treatment, indicating a complex interplay between EBV and HLH.
• Anti-PD-1 therapy provided only transient control of EBV viremia.
• The patient developed aggressive large B-cell lymphoma, complicating the clinical picture.
• Severe chemotherapy-related myelosuppression and sepsis ultimately led to multi-organ failure and death.

Clinical Implications

This case underscores the diagnostic challenges in identifying lymphoid neoplasms in patients with EBV-associated immune dysregulation. Clinicians should be vigilant for HLH in patients with multiple myeloma and consider the potential for concurrent lymphoid malignancies. The limited efficacy of PD-1 blockade suggests the need for alternative therapeutic strategies in managing EBV-related complications.

Conclusion

The interplay between EBV, HLH, and multiple myeloma presents significant clinical challenges. This case highlights the importance of comprehensive diagnostic approaches and the need for tailored treatment strategies in complex hematological conditions.

Related Resources & Content

1. Blood Cancer Journal, 2023 -- Multi-Omics Analysis of Three Hematological Cancers in a Patient Identifies Their Origin from Clonal Hematopoietic Stem Cells
2. Gastrointestinal Involvement in EBV-Related Lymphoproliferative Disorders Mimicking Inflammatory Bowel Disease in Immunocompetent Individuals: Case Studies and Review of Existing Literature, 2019
3. Blood Cancer Journal, 2021 -- Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing
4. Blood Cancer Journal, 2026 -- Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies
5. Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria, 2025
6. Hemophagocytic Lymphohistiocytosis | New England Journal of Medicine
7. Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis - PMC
8. Multicenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria
9. Haemophagocytic lymphohistiocytosis in critically ill adults: a single-centre retrospective ICU cohort study - PMC
10. Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis - PubMed
11. Assessing the effectiveness of etoposide treatment in adult haemophagocytic lymphohistiocytosis: a systematic review and meta-analysis | Clinical and Experimental Medicine | Springer Nature Link
12. Uemura Y, Yamamoto M, Ishimura M, et al. JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Blood Neoplasia. 2025;2(1):100053 - PMC
13. Exploratory study of PD-1 inhibitors with or without ruxolitinib for the treatment of adult EBV-associated hemophagocytic lymphohistiocytosis: a real-world data-based preliminary investigation - PMC
14. Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study - PMC
15. The clinical features and outcomes of aggressive large B cell lymphoma with concomitant hemophagocytic lymphohistiocytosis at diagnosis | Annals of Hematology | Springer Nature Link
16. Hemophagocytic Lymphohistiocytosis as First Manifestation of Dual B‐Cell Neoplasms: A Case Report of Co‐Existing Multiple Myeloma and B‐Cell Lymphoma - PMC
17. Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH) | Orphanet Journal of Rare Diseases | Springer Nature Link